19 results about "Babesia" patented technology

The invention provides a method for simultaneously detecting three hematogenous parasites based on RAA-LFS and application of the method. The method comprises the following steps: firstly, screening target genes of genomic DNA of specific amplified toxoplasma gondii, babesia and plasmodium and primers of the target genes; a primer and probe combination for specifically amplifying the 18s rRNA-1 gene of the toxoplasma gondii, the 18s rRNA-2 gene of the babesia and the 18s rRNA-3 gene of the plasmodium is determined; rapid multiple detection is completed in a reaction system by utilizing an RAA constant-temperature amplification technology, and a detection result is intuitively judged by combining a lateral flow chromatography test strip, so that the detection efficiency is greatly improved, and the result can be obtained in a short time. The RAA-LFS detection method provided by the invention has remarkable advantages in application scenes such as epidemic disease prevention and control or blood screening.

The invention belongs to the field of biological medicine, and particularly relates to application of camostat mesylate in preparation of medicine for preventing or treating babesia disease. Through screening in an MCE compound library, it is accidentally found that the compound camostat mesylate can reduce the infection rate of the Caibeisia dunnii and inhibit growth of the Caibeisia dunnii, has small toxicity to host cells, can be used as a candidate drug for preventing and treating the babesia dunnii, and has important significance.

This invention provides a method for simultaneous detection of three bloodborne parasites based on RAA-LFS and its applications. First, target genes and primers for specifically amplifying the genomic DNA of Toxoplasma gondii, Babesia, and Plasmodium are screened, identifying primer and probe combinations specifically for amplifying the 18S rRNA-1 gene of Toxoplasma gondii, the 18S rRNA-2 gene of Babesia, and the 18S rRNA-3 gene of Plasmodium. Using RAA isothermal amplification technology, rapid multiplex detection is achieved in a single reaction system. Combined with lateral flow chromatography test strips for intuitive result interpretation, detection efficiency is greatly improved, and results are obtained in a short time. The RAA-LFS detection method provided by this invention has significant advantages in applications such as epidemic prevention and control or blood screening.

The present invention relates to a Babesia antigen comprising at least a portion of a gametocyte HAPLESS2 / GCS1 (HAP2) protein, vectors and cells expressing such antigen, compositions and kits comprising such antigens, and methods of using such antigens to interfere with the Babesia transmission by competent ticks.

The present invention relates to the application of a phenylurea compound as a Babesia growth inhibitor, belonging to the field of pharmaceutical technology. The phenylurea compound is 1,3-bis(3-chlorophenyl)urea or 1,3-bis(3-cyanophenyl)urea. The two phenylurea compounds have a small molecular weight, a relatively simple structure, are soluble in a variety of solvents, and have unique structures and chemical properties. Experiments have shown that both phenylurea compounds can be used as Babesia growth inhibitors and can effectively inhibit the growth of Babesia. In addition, the two phenylurea compounds have good bioavailability and safety characteristics, have no obvious toxic side effects on host cells, and have broad application prospects.

The present invention discloses a primer-probe combination, method and use for simultaneously detecting three protozoa from giant pandas, belonging to the technical field of protozoal disease detection from giant pandas. The primer-probe combination includes specific primers and TaqMan probes for detecting the three protozoa, and the specific sequences are shown in SEQ ID NOs. 1 to 9. The present invention designs three pairs of specific primers and three TaqMan probes for the specific regions of Babesia giant panda, Hepatozoon spp., and Toxoplasma gondii, and establishes a triple fluorescent quantitative PCR detection method that can simultaneously identify Babesia giant panda, Hepatozoon spp., and Toxoplasma gondii in a single PCR. The detection method has good specificity and accuracy, high sensitivity, high detection efficiency, no cross-reaction, and saves time and sample usage, providing a new option for the simultaneous detection of three protozoa from giant pandas.

The invention discloses a quadruple fluorescent quantitative PCR (Polymerase Chain Reaction) detection method for simultaneously detecting multiple pathogens in bovine red blood cells. The method comprises the following steps: acquiring core functional gene sequences of four pathogens; carrying out gene sequence comparison, and screening out continuous conservative fragments; comparing the conserved sequence with the bovine genome and the homology of the microorganisms to obtain a specific conserved sequence; designing four pairs of PCR primers with the same annealing temperature, and designing a probe; selecting a gene sequence fragment, treating the gene sequence fragment with restriction enzyme, and connecting a target gene fragment with a T vector by using DNA (Deoxyribose Nucleic Acid) ligase; transforming the connection product into competent cells for culture, determining successful cloning, and extracting plasmids; the PCR primer and the probe are tested for multiple times, and the annealing temperature and the component concentration of a reaction system are adjusted. By implementing the method disclosed by the invention, babesia, theileria, anaplasma and eperythrozoon can be detected at the same time, the diagnosis efficiency is remarkably improved, and the risk of missed diagnosis is reduced.

Vaccine compositions comprising a plurality of immunogens attached to a carrier for inducing an immune response against a pathogen selected from the Anaplasma, Babesia, Borrelia, and Chlamydia genera. Vaccine compositions comprising multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing an infection caused by the Anaplasma, Babesia, Borrelia, or Chlamydia pathogens, and the related diseases thereof.

There is described herein a method for specifically detecting Babesia species nucleic acid in a sample, which in one aspect comprises: (1) contacting a sample, said sample suspected of containing Babesia species nucleic acid, with at least two oligomers for amplifying a target region of a Babesia species target nucleic acid, wherein the at least two amplification oligomers comprise: (a) a first amplification oligomer comprising a first target-hybridizing sequence (i) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:66 and comprises SEQ ID NO:56 or 57; or (ii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:96 and comprises SEQ ID NO:101; or (iii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:97 and comprises SEQ ID NO:101; (iv) comprises or consists of SEQ ID NO:8; (v) comprises or consists of SEQ ID NO:83 and (b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 33 contiguous nucleotides in length, and (i) is contained in SEQ ID NO:68 and comprises SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or SEQ ID NO:85; or (ii) is contained in SEQ ID NO:67 and comprises SEQ ID NO:45 or SEQ ID NO:52; or (iii) is contained in SEQ ID NO:70 and comprises SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, or SEQ ID NO:51; (2) performing an in vitro nucleic acid amplification reaction, wherein any Babesia target nucleic acid present in said sample is used as a template for generating an amplification product; and (3) detecting the presence or absence of the amplification product, thereby indicating the presence or absence of Babesia species target nucleic acid in said sample.

The invention provides application of babesia orientalis thioredoxin peroxidase 2 in preparation of a detection kit for babesia orientalis disease, and belongs to the technical field of molecular biology. The amino acid sequence of the babesia orientalis thioredoxin peroxidase 2 provided by the invention is shown as Seq2, and the nucleotide sequence of the coding gene of the babesia orientalis thioredoxin peroxidase 2 is shown as Seq1. The babesia orientalis thioredoxin peroxidase 2 provided by the invention has good immunogenicity, a generated antibody is good in specificity, high in sensitivity and simple to operate, and the babesia orientalis thioredoxin peroxidase 2 can be applied to related detection kits of babesia orientalis diseases through verification of immunoblotting and indirect immunofluorescence experiments.

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.

The present invention discloses a monoclonal antibody against the ALD protein of Babesia duncani, secreted by hybridoma cell line 2A9, which has been deposited with the China Center for Type Culture Collection under the accession number CCTCC C2024203. The amino acid sequence of the ALD protein is shown in SEQ ID NO: 2, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO: 1. The present invention also discloses an indirect immunofluorescence method for detecting Babesia duncani using the monoclonal antibody, providing a powerful means and tool for the clinical prevention and control of Babesia duncani, a major zoonotic parasite, and having significant significance for preventing the occurrence of the disease.

The invention discloses a quadruple fluorescent quantitative PCR (Polymerase Chain Reaction) detection method for simultaneously detecting multiple pathogens in red blood cells of cattle and sheep. The method comprises the following steps: acquiring core functional gene sequences of four pathogens; carrying out gene sequence comparison, and screening out continuous conservative fragments; comparing the conserved sequence with cattle and sheep genomes and the homology of microorganisms to obtain a specific conserved sequence; designing four pairs of PCR primers with the same annealing temperature, and designing a probe; selecting a gene sequence fragment, treating the gene sequence fragment with restriction enzyme, and connecting a target gene fragment with a T vector by using DNA (Deoxyribose Nucleic Acid) ligase; transforming the connection product into competent cells for culture, determining successful cloning, and extracting plasmids; the PCR primer and the probe are tested for multiple times, and the annealing temperature and the component concentration of a reaction system are adjusted. By implementing the method disclosed by the invention, babesia, theileria, anaplasma and eperythrozoon can be detected at the same time, the diagnosis efficiency is remarkably improved, and the risk of missed diagnosis is reduced.

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.

The invention provides application of Duncan babesia dunnii TPx-2 protein in preparation of a detection kit for Duncan babesia dunnii disease, and belongs to the technical field of molecular biology. According to the application of the TPx-2 protein provided by the invention in preparation of the detection kit for the dunnii dunnii disease, the amino acid sequence of the TPx-2 protein is shown as Seq2. The Duncan-dunnii TPx-2 protein provided by the invention can effectively detect the existence of Duncan-dunnii in mouse blood, and has good immunogenicity, and the generated antibody has good specificity and high sensitivity. Therefore, the dunnii dunnii TPx-2 protein and the antibody generated by the dunnii dunnii TPx-2 protein can be used for detecting the dunnii dunnii disease and can be applied to a detection kit.

The invention belongs to the field of life medicine science, and particularly relates to application of iron nanoparticles in preparation of a product for preventing and treating babesia. The iron nanoparticles are polysaccharide superparamagnetic iron oxide injection or other molded products containing main curative effect components of the polysaccharide superparamagnetic iron oxide injection, and the iron nanoparticles are applied to an object in the presence of a magnetic field. Tests prove that the iron nanoparticles have a good control effect on babesia with weak fecundity under the action of an external magnetic field.

Self-adjuvanting vaccine compositions comprising at least one modified immunogen via in vitro glycosylation methods that provide a rational approach for generating glycosylated versions of immunogens via the reducing end of a linear carbohydrate, the reducing end containing an N-acyl-2-amino moiety. Self-adjuvanting vaccine compositions comprising a plurality of heterologous immunogens associated with a multivalent carrier, wherein at least one immunogen is glycosylated to allow for mucosal delivery. Self-adjuvanting vaccine compositions comprising multivalent carriers and related methods using the self-adjuvanting vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection. Pathogens for which this approach may be useful include, but are not limited to, influenza viruses, rhinoviruses, human immunodeficiency viruses (HIV), respiratory syncytial virus (RSV), coronaviruses, Babesia, Borrelia, Neisseria, and Chlamydia, and the related diseases thereof.

The disclosure, in some aspects, provides a composition comprising labelled and / or tagged and / or bound amino acid sequences useful for the detection of Babesia species. Also disclosed are methods for the detection of infection by one or more Babesia species.

The present disclosure relates to methods of treating infections caused by one or more protozoa such as Cryptosporidium, Eimeria, Babesia and Toxoplasma comprising administering to a subject in need thereof an effective amount of an inhibitor of plasmepsin IX and / or X selected from compounds disclosed herein.